Balchem Corporation · NASDAQ:BCPC
Balchem — Q3 2025 Earnings Presentation
36 slides from Balchem's earnings presentation, October 2025
Slide 1: Investor Presentation Q3 2025
Investor Presentation Q3 2025. 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement • During the course of this presentation, management may make forward-looking statements regarding financial performance and future events. • These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "foreca
Slide 3: Agenda
Agenda 01 Q3 2025 Key Takeaways 05 Corporate Social Responsibility 02 Balchem Overview 06 Wrap Up 03 Vision and Strategic Focus 07 Appendix GAAP to Non-GAAP reconciliations 04 Financial Performance & Capital Allocation 3
Slide 4: Q3 Key Takeaways
Q3 Key Takeaways Balchem continues to deliver strong growth +11.5% 1. Strong financial performance continued in Q3 with double digit sales and earnings growth Q3 Sales vs. PY 2. Strong cash flows supporting a healthy balance sheet 3. All three business segments delivering solid growth on the top +11
Slide 5: Agenda
Agenda 01 Q3 2025 Key Takeaways 05 Corporate Social Responsibility 02 Balchem Overview 06 Wrap Up 03 Vision and Strategic Focus 07 Appendix GAAP to Non-GAAP reconciliations 04 Financial Performance & Capital Allocation 5
Slide 6: Balchem Corporation At a Glance
Balchem Corporation BCPC At a Glance NASDAQ 2024 Sales $954 Million Approximate number of employees 1,400 2024 Adjusted EBITDA $250 Million Founded in 2024 Adjusted EBITDA margin 1967 26.3% 6
Slide 7: Three Business Segments – 2024 Revenue
Three Business Segments – 2024 Revenue Human Nutrition & Health Animal Nutrition & Health Specialty Products Human Nutrition & Health Animal Nutrition & Health Specialty Products 63% 23% 14% Provides a range of branded specialty Supplies science-based animal feed Provides critical sterilization tech
Slide 8: Balchem Corporation
Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that help make the world a healthier place. Corporate Headquarters: Montvale, NJ 22 Manufacturing Sites 8 Technology Centers 8 Regional Offices 8
Slide 9: Executive Leadership
Executive Leadership Ted Harris Chairman, President, and CEO • Joined Balchem in May 2015 • Prior to Balchem was a Senior VP of Ashland Inc. where he held a series of senior leadership roles over 10+ years • Independent director on the Board of Directors of Pentair plc • MBA from Harvard University
Slide 10: Value Proposition
Value Proposition Technologies Value to our customers • High efficacy nutrients essential for life • Enhanced animal health and feed productivity • Functional ingredient systems formulations and applications expertise • Crop protection and yield improvement • Complete supply chain capabilities and a
Slide 11: Segment Overview
Segment Overview Leveraging Solutions Across Segments Segment Markets Served Solutions 14% Human Nutrition • Nutritional Supplements • Microencapsulation 2024 & Health • Sport & Active Nutrition • Choline and Vitamin K2 23% Revenue • Infant and Toddler Formula • Chelated Minerals by • Healthy Snacki
Slide 12: Agenda
Agenda 01 Q3 2025 Key Takeaways 05 Corporate Social Responsibility 02 Balchem Overview 06 Wrap Up 03 Vision and Strategic Focus 07 Appendix GAAP to Non-GAAP reconciliations 04 Financial Performance & Capital Allocation 12
Slide 13: Our Vision, Mission and Core Values
Our Vision Our Mission is clear – to make is focused – to build a global the world a healthier nutrition and health company place. delivering trusted, innovative and science-based solutions to our customers. Our Core Values Always Collaborating Playing Staying Doing the and Growing to and Acting on
Slide 14: How Do We Make the World a Healthier Place?
How Do We Make the World a Healthier Place? Provide food, beverage, and Improve nutrient bioavailability Support prenatal, infant, and Help farmers grow crops that Provide nutritious foods for dietary supplement ingredients for animals, reducing feed inputs toddler health with targeted are hardier w
Slide 15: Strategic Focus
Strategic Focus 01 02 03 04 Strengthening Driving Organic Strategic M&A Excellence in Positions in Attractive, Growth Execution Growing Markets Building scale, adding Creating new demand Augmenting organic Maintaining a strong adjacent capabilities, through innovation, market growth and accelerating
Slide 16: Growth Platforms
Growth Platforms Multiple Platforms to Drive Growth Above Market Growth Nutrient delivery Specialty Performance Functional Nutrients systems for Solutions Gases Science-backed Dairy and Beef Delivering high protein, Health and safety portfolio of branded high fiber or clean label Rumen-bypass precis
Slide 17: Agenda
Agenda 01 Q3 2025 Key Takeaways 05 Corporate Social Responsibility 02 Balchem Overview 06 Wrap Up 03 Vision and Strategic Focus 07 Appendix GAAP to Non-GAAP reconciliations 04 Financial Performance & Capital Allocation 17
Slide 18: Q3 2025 Financial Summary
Q3 2025 Financial Summary Double-digit sales and profit growth Sales Adj. EBITDA Adj. Net Earnings Adj. EPS $M $M $M $/share ↑ 11.5% ↑ 11.0% ↑ 19.1% ↑ 19.5% 71.4 1.35 267.6 44.0 64.4 239.9 36.9 1.13 3Q24 3Q25 3Q24 3Q25 3Q24 3Q25 3Q24 3Q25 Strong growth in all three Driven by sales growth across the
Slide 19: YTD 2025 Financial Summary
YTD 2025 Financial Summary Sales growth, margin expansion, and profit growth Sales Adj. EBITDA Adj. Net Earnings Adj. EPS $M $M $M $/share ↑ 8.4% ↑ 10.4% ↑ 18.4% ↑ 18.2% 207.0 125.6 3.84 773.5 713.7 187.5 106.1 3.25 YTD24 YTD25 YTD24 YTD25 YTD24 YTD25 YTD24 YTD25 Strong growth in all three Driven by
Slide 20: Historical Financials
Historical Financials Consistent performance over the years Sales Adj. EBITDA $M +8.2% $M +9.4% 250 CAGR 942 922 954 CAGR 231 216 207 799 774 190 704 174 644 160 2019 2020 2021 2022 2023 2024 YTD 2025 2019 2020 2021 2022 2023 2024 YTD 2025 Adj. Net Earnings Adj. EPS $M $/share +6.6% CAGR 143 +6.5% 1
Slide 21: Capital Allocation Strategy
Capital Allocation Strategy Capital Allocation Priorities Annual Cash Flow and Net Debt Leverage Ratio • Support organic growth opportunities 2.3 • Augment growth with targeted M&A • Diligent debt service 1.6 1.7 1.5 • Continue to pay and grow dividend 1.2 1.1 1.1 • Stock buy-backs for anti-dilution
Slide 22: Free Cash Flow Conversion
Free Cash Flow Conversion Translating profits into cash Free Cash Flow as % of Non-GAAP Net Earnings 116% 109% 107% 105% 103% 102% 102% 100% 93% 100% 79% 69% 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Q3 2025 TTM* * TTM: Trailing Twelve Months 22
Slide 23: Key Acquisitions
Key Acquisitions Augmenting Organic Growth with Targeted Acquisitions Close to Core Kappa Bioscience • Portfolio extension in high growth specialty vitamin market • Vitamin K2 and MK-7 Albion Minerals Bioscreen • Adjacent product offering • Geographic expansion and Bergstrom Nutrition in high growth
Slide 24: Dividends
Dividends Consistent dividend policy ($/share) 0.87 +11.2% 0.79 Annual double-digit dividend growth for CAGR 0.71 the last decade 0.64 0.58 0.52 0.47 0.42 Consistency in 0.38 0.34 0.30 execution 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 24
Slide 25: Agenda
Agenda 01 Q3 2025 Key Takeaways 05 Corporate Social Responsibility 02 Balchem Overview 06 Wrap Up 03 Vision and Strategic Focus 07 Appendix GAAP to Non-GAAP reconciliations 04 Financial Performance & Capital Allocation 25
Slide 26: Sustainability
Sustainability Our Sustainability Objectives & Framework Company Provide innovative solutions for the health 1.2 billion people Making & nutritional needs of the world reached in 2024 the The total number of people impacted is calculated by world a measuring the annual consumption of protein and the
Slide 27: Recent Sustainability Progress
Recent Sustainability Progress Scope 3 Learn more 7th about our sustainability GHG emissions successfully programs: measured and reported sustainability report released in April 2025 4th anniversary of UN Global Compact Surpassed our 2030 GHG emissions reduction goal, by reducing Scope 1 and 2 commi
Slide 28: Agenda
Agenda 01 Q3 2025 Key Takeaways 05 Corporate Social Responsibility 02 Balchem Overview 06 Wrap Up 03 Vision and Strategic Focus 07 Appendix GAAP to Non-GAAP reconciliations 04 Financial Performance & Capital Allocation 28
Slide 29: Balchem Summary
Balchem Summary A global nutrition and health company delivering trusted, innovative and science-based solutions to our customers Leading positions Creating new Strong financial Proven track in attractive demand through performance, record and markets innovation delivering healthy well positioned ma
Slide 30: Agenda
Agenda 01 Q3 2025 Key Takeaways 05 Corporate Social Responsibility 02 Balchem Overview 06 Wrap Up 03 Vision and Strategic Focus 07 Appendix GAAP to Non-GAAP reconciliations 04 Financial Performance & Capital Allocation 30
Slide 31: Non-GAAP Financial Information
Non-GAAP Financial Information In addition to disclosing financial results in accordance with United States (U.S.) generally accepted accounting principles (GAAP), this earnings release contains non-GAAP financial measures that we believe are helpful in understanding and comparing our past financial
Slide 32: Non-GAAP Financial Information
Non-GAAP Financial Information Reconciliation of Non-GAAP Measures to GAAP (Dollars in thousands, except per share data; unaudited) Three Months Nine Months Ended September 30, Ended September 30, Reconciliation of adjusted earnings from operations 2025 2024 2025 2024 GAAP earnings from operations $
Slide 33: Non-GAAP Financial Information
Non-GAAP Financial Information Reconciliation of GAAP Net Earnings to EBITDA and to Adjusted EBITDA (Dollars in thousands; unaudited) Three Months Nine Months Ended September 30, Ended September 30, 2025 2024 2025 2024 Net earnings – as reported $40,289 $33,837 $115,620 $94,892 Add back: Provision f
Slide 34: Non-GAAP Financial Information
Non-GAAP Financial Information Reconciliation of GAAP Effective Income Tax Rate to Non-GAAP Effective Income Tax Rate (Dollars in thousands; unaudited) Three Months Nine Months Ended September 30, Ended September 30, 2025 2024 2025 2024 GAAP Income Tax Expense $11,755 $10,056 $33,375 $27,077 GAAP Ef
Slide 35: Non-GAAP Financial Information
Non-GAAP Financial Information (1) Amortization of intangible assets and finance leases: Amortization of intangible assets and finance leases consists of amortization of customer relationships, trademarks and trade names, developed technology, regulatory registration costs, patents and trade secrets
Slide 36: Balchem
balchem lve Today. Shape Tomorrow.